Regulatorische T‑Zellen beim systemischen Lupus erythematodes

Ohl, Kim; Tenbrock, Klaus

doi:10.1007/s00393-016-0060-z

Cited by 6 publications

(1 citation statement)

References 123 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CD25 is persistently expressed in CD4+ FoxP3+ Tregs, when IL-2 activated CD25 forming high affinity IL-2R to compete for available IL-2 in the circulation ( 113 ). The decrease in IL-2 level was found to be associated with a depleted Treg cell population, and its reversibility by IL-2 therapy provides important reasons for the treatment of lupus ( 114 , 115 ). High doses administration of recombinant human IL-2 (rIL-2) can aid conventional T cells and naïve CD8+ T cells that produce perforin, granzymes, IL-5, IL-13, and IFN-γ ( 116 ).…”

Section: Therapeutic Potential Of Regulatory Cells In Slementioning

confidence: 99%

Pathogenesis and novel therapeutics of regulatory T cell subsets and interleukin-2 therapy in systemic lupus erythematosus

Tsai,

Liao,

Hsiao

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) is a heterogeneous multisystem inflammatory disease with wide variability in clinical manifestations. Natural arising CD4+ regulatory T cells (Tregs) play a critical role in maintaining peripheral tolerance by suppressing inflammation and preventing autoimmune responses in SLE. Additionally, CD8+ regulatory T cells, type 1 regulatory T cells (Tr1), and B regulatory cells also have a less well-defined role in the pathogenesis of SLE. Elucidation of the roles of various Treg subsets dedicated to immune homeostasis will provide a novel therapeutic approach that governs immune tolerance for the remission of active lupus. Diminished interleukin (IL)-2 production is associated with a depleted Treg cell population, and its reversibility by IL-2 therapy provides important reasons for the treatment of lupus. This review focuses on the pathogenesis and new therapeutics of human Treg subsets and low-dose IL-2 therapy in clinical benefits with SLE.

show abstract

Section: Therapeutic Potential Of Regulatory Cells In Slementioning

confidence: 99%

Pathogenesis and novel therapeutics of regulatory T cell subsets and interleukin-2 therapy in systemic lupus erythematosus

Tsai,

Liao,

Hsiao

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

show abstract

IL-2-Therapy in SLE- Selective reconstitution of immunological tolerance

Humrich

Riemekasten

2016

Z Rheumatol

View full text Add to dashboard Cite

Deep Neck Infection in Systemic Lupus Erythematosus Patients: Real-World Evidence

Chang

Lin

et al. 2020

Sci Rep

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) might increase deep neck infection (DNI) risk, but evidencesupporting this hypothesis is limited. In this retrospective follow-up study, the SLE-DNI association was investigated using data from the Registry for Catastrophic Illness Patients, which is a subset of the Taiwan National Health Insurance Research Database. All patients newly diagnosed as having SLE in 1997-2011 were identified, and every SLE patient was individually matched to four patients without SLE according to sex, age, and socioeconomic status. The study outcome was DNI occurrence. DNI treatment modalities and prognoses in SLE and non-SLE patients, along with the association of steroid dose with DNI risk, were also studied. In total, 17,426 SLE and 69,704 non-SLE patients were enrolled. Cumulative DNI incidence was significantly higher in the SLE cohort than in the non-SLE cohort (p < 0.001). The Cox regression model demonstrated that SLE significantly increased DNI risk (hazard ratio: 4.70; 95% confidence interval: 3.50-6.32, p < 0.001). Moreover, in the sensitivity and subgroup analyses, the effect of SLE on DNI was stable. Relatively few SLE-DNI patients received surgical interventions (15.6% vs. 28.6%, p = 0.033). The between-group differences in tracheostomy use and hospitalisation duration were nonsignificant. In SLE patients, high steroid doses significantly increased Dni incidence (≥3 vs. <3 mg/day = 2.21% vs. 0.52%, p < 0.001). This is the first study demonstrating that SLE increases DNI risk by approximately five times and that high steroid dose increases DNI incidence in SLe patients. The prevalent infectious disease deep neck infection (DNI) is typically encountered in emergency departments.Patients with DNI typically require intensive care and aggressive treatment. DNI has the likelihood to be life threatening, notably in systemic disease patients and elderly individuals 1-3 . Immunocompromised patients do not show usual symptoms of DNI, making its early diagnosis difficult, possibly increasing complications and mortality 1,3-5 . Therefore, investigating the influence of immunosuppressing diseases on DNI is important.Systemic lupus erythematosus (SLE) renders its affected patients vulnerable to infection; in addition, in such patients undergoing dialysis, infection is a notable cause of mortality 6-9 . SLE activity itself and long-term usage of immunosuppressants are considered the two main causes for infection susceptibility 6,10 . In their case series of 130 patients with DNI, Yang et al. 11 reported two cases of DNI in patients with SLE under steroid therapy. However, the influence of SLE on DNI was not investigated in depth. In addition, the association between the duration of SLE, steroid dosage, and DNI risk remains unknown. We therefore conducted this real-world study with the primary purpose of probing the influence exerted by SLE on DNI incidence, treatment, and prognosis.

show abstract

Regulatorische T‑Zellen beim systemischen Lupus erythematodes

Cited by 6 publications

References 123 publications

Pathogenesis and novel therapeutics of regulatory T cell subsets and interleukin-2 therapy in systemic lupus erythematosus

Pathogenesis and novel therapeutics of regulatory T cell subsets and interleukin-2 therapy in systemic lupus erythematosus

IL-2-Therapy in SLE- Selective reconstitution of immunological tolerance

Deep Neck Infection in Systemic Lupus Erythematosus Patients: Real-World Evidence

Contact Info

Product

Resources

About